Milestone Pharmaceuticals is scheduled to resume trading at 7:30 am ET, with quotation set to resume at 7:25 am ET, according to Nasdaq. Shares had been halted for news pending ahead of the company announcing it had received a Refusal to File letter from the FDA for the New Drug Application for self-administered etripamil nasal spray for the treatment of paroxysmal supraventricular tachycardia.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on MIST:
- Milestone Pharmaceuticals Receives Refusal to File Letter from U.S. FDA for New Drug Application for Etripamil in the Treatment of PSVT
- Milestone selloff on serious adverse event overdone, says H.C. Wainwright
- Milestone Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Clinical and Corporate Updates
- Milestone presents results from ReVeRA Phase 2 study of Etripamil in AFib-RVR
